ArrowMark Colorado Holdings’s Krystal Biotech KRYS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-30,544	Closed	-$1.32M	–	314
2020 Q1	$1.32M	Hold	30,544	–	–	0.02%	235
2019 Q4	$1.69M	Hold	30,544	–	–	0.02%	251
2019 Q3	$1.06M	Hold	30,544	–	–	0.01%	247
2019 Q2	$1.23M	Hold	30,544	–	–	0.01%	267
2019 Q1	$1M	Buy	30,544 +1,821	+6%	+$42.9K	0.01%	276
2018 Q4	$597K	Buy	+28,723	New	+$601K	0.01%	309

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ArrowMark Colorado Holdings's KRYS Position: Q2 2020 in Review

ArrowMark Colorado Holdings sold out of Krystal Biotech (KRYS) in Q2 2020, closing a stake of 30,544 shares — an estimated $1.32M sold.

ArrowMark Colorado Holdings first reported a position in KRYS in Q4 2018 and held it in 6 quarters. The position peaked at $1.69M in Q4 2019. 110 funds tracked by Wall St. Rank hold KRYS as of Q2 2020.

ArrowMark Colorado Holdings reported no remaining Krystal Biotech position as of Q2 2020 after selling out during the quarter.
ArrowMark Colorado Holdings sold 30,544 Krystal Biotech shares in Q2 2020, an estimated $1.32M.
ArrowMark Colorado Holdings first reported a position in Krystal Biotech in Q4 2018 and held it in 6 quarters.
ArrowMark Colorado Holdings's Krystal Biotech position peaked at $1.69M in Q4 2019.
110 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2020, filed 14 Aug 2020.